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Abstract
Hepatitis C virus (HCV) causes acute and chronic hepatitis which can eventually lead to permanent liver damage,
hepatocellular carcinoma and death. Currently, there is no vaccine available for prevention of HCV infection due to
high degree of strain variation. The current treatment of care, Pegylated interferon a in combination with ribavirin
is costly, has significant side effects and fails to cure about half of all infections. In this review, we summarize
molecular virology, replication and immune responses against HCV and discussed how HCV escape from adaptive
and humoral immune responses. This advance knowledge will be helpful for development of vaccine against HCV
and discovery of new medicines both from synthetic chemistry and natural sources.
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Background
H e p a t i t i sCv i r u s( H C V )i n f e c t i o ni sas e r i o u sg l o b a l
health problem that affects 180 million people world-
wide and 10 million people in Pakistan [1]. It is esti-
mated that three to four million people are infected
with HCV every year [2]. Hepatitis C virus (HCV)
causes acute and chronic hepatitis which can eventually
lead to permanent liver damage and hepatocellular car-
cinoma [2]. Of those acutely infected with HCV, around
85% develop chronic infection. Approximately 70% of
patients with chronic viremia develop chronic liver dis-
ease, 10-20% of which develop liver cirrhosis. Hundreds
of thousands of people die each year from liver failure
and liver cancer caused by this disease.
HCV is a small enveloped virus with a positive-sense,
single-stranded RNA genome that encodes a large poly-
protein of 3010 amino acids. The polyprotein is co- and
posttranslationally processed by cellular and virally
encoded proteases to produce the mature structural and
non-structural (NS) proteins. Among the NS proteins,
t h eN S 3s e r i n e - l i k ep r o t e a s ea n dt h eR N A - d e p e n d e n t
RNA polymerase (RdRp) are essential for viral matura-
tion and replication, and therefore represent ideal
targets for the development of small molecule anti-HCV
compounds (Figure 1) [3,4].
HCV Structural Proteins
Core protein
HCV core is a highly conserved basic protein which
makes up the viral nucleocapsid. Core consists of HCV
first 191 amino acids and can be divided into three
domains on the basis of hydrophobicity. Domain 1
(amino acids 1 - 117) contains mainly basic residues with
two short hydrophobic regions. Domain 2 (amino acids
118 - 174) is less basic and more hydrophobic and its C
-terminus is at the end of p21. Domain 3 (amino acids
175 - 191) is highly hydrophobic and acts as a signal
sequence for E1 envelope protein [5]. Core protein can
bind viral RNA [6] via domain 1 (amino acids 1 - 74).
Core is a cytosolic membrane-bound protein, which has
been found to associate with the endoplasmic reticulum
(ER), lipid droplets, mitochondria and the nucleus. Core
protein directly or indirectly involved in hepatocarcino-
genesis and steatosis hepatitis [7,8]. HCV core protein
interacts with numerous cellular proteins and to affect
host cell functions such as gene transcription, lipid meta-
bolism, apoptosis and various signaling pathways [9]
Envelope glycoproteins
HCV consist of two “envelop proteins” E1 and E2
(Figure 1). These proteins are highly glycosylated and
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fusogenic subunit and that E2 acts as the receptor bind-
ing subunit of the HCV envelope. The E1 envelope gly-
coprotein of HCV contains 4 to 5 N-linked glycans and
the E2 envelope glycoprotein has 11 N-glycosylation
sites [10,11]. However the numbers of glycosylation sites
vary according to genotype. Glycosylation sites on E1
and E2 are highly conserved and contain a mixture of
complex and high-mannose side-chains. HCV glycans
play an important role in envelope glycoprotein folding
and formation of the HCV E1E2 complexes, receptor
interactions with virus. [11] and antigenic variation [12].
The envelope proteins are thought to mediate cell
entry by recognition of cellular membrane receptor pro-
teins. However, until recently, research in this area was
difficult due to the lack of infectious cell based systems.
The development of cells, which produce infectious
HCV pseudotype particles (HCVpp) by the use of a ret-
roviral vector for assembly of the virus pseudoparticle
has helped the identification of cellular receptors [13].
Furthermore, HCVpp could be neutralised by anti-E2
monoclonal antibodies [14]
Various putative cellular receptors have been sug-
gested as mediating interactions with HCV envelope
proteins. Truncated forms of E2 have been shown to
interact with CD81, scavenger receptor type B class 1
protein (SRB-1) and high density lipoprotein (HDL)
binding molecule [15,16]. Soluble forms of CD81 can
inhibit entry of HCVpp to cells [14]. Ectopic expression
of CD81 in CD81-negative cells does not permit HCVpp
entry indicating that CD81 is a co-receptor. Another
proposed HCV receptor is the low density lipoprotein
(LDL) receptor, which was shown to help endocytosis of
the virus. Viral entry could be prevented in a number of
cell types using an anti-LDL monoclonal antibody [17].
Mannose binding proteins (DC-SIGN and L-SIGN) have
been suggested as to have interactions with E2 but their
contribution to viral entry is not known [18].
E2 contains two hypervariable regions (HVR), HVR1
and HVR2, which are under constant selection for
mutation probably because they are targets for neutraliz-
ing antibodies. Numerous studies have highlighted the
genetic heterogeneity of the HVR1, which may enable
virus to evade the immune system and facilitate estab-
lishment of chronic infection [19,20]. However, chronic
infection has been reported in an experimentally
infected chimpanzee even though there was no variation
in HVR [21].
P7 Protein
P7 is a 63-amino acid polypeptide located between HCV
E2 and NS2 genes. P7 is a membrane-spanning protein
located in the Endoplasmic Reticulum (ER). The clea-
vage of p7 is mediated by the ER signal peptidases of
the host cell. Two transmembrane domains (TMDs) of
P7 are connected by a cytoplasmic loop and oriented
towards the ER lumen. It also has been demonstrated
that the carboxyl-terminal TMD of P7 can function as a
signal sequence that most likely promotes the transloca-
tion of NS2 into the ER lumen for appropriate cleavage
by host signal peptidases. These proteins form ion chan-
nels that play an essential role in virus infection [22].
HCV P7 has characteristics similar to those of a group
of proteins called viroporins. P7 has been shown to be
Figure 1 Proteins encoded by the HCV genome. HCV is formed by an enveloped particle harbouring a plus-strand RNA of 9.6 kb. The
genome carries a long openreading frame (ORF) encoding a polyprotein precursor of 3010 amino acids. Translation of the HCV ORF is directed
via a 340 nucleotide long 5’ nontranslated region (NTR) functioning as an internal ribosome entry site; it permits the direct binding of ribosomes
in close proximity to the start codon of the ORF. The HCV polyprotein is cleaved co- and post-translationally by cellular and viral proteases into
ten different products, with the structural proteins (core (C), E1 and E2) located in the N-terminal third and the nonstructural (NS2-5) replicative
proteins in the remainder. Putative functions of the cleavage products are shown [4].
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tious virions in a genotype specific manner [23].
Nonstructural proteins
NS2
NS2 protein is a 21-23 kDa transmembrane protein.
NS2 protein is essential for completion of the viral repli-
cation cycle in vitro and in vivo [24,25]. NS2 contains
highly hydrophobic N-terminal residues forming three
or four transmembrane helices that insert into the ER
membrane. The C-terminal part of NS2 presumably
resides in the cytoplasm play an important role in NS2/
3 auto protease activity together with the N-terminal
domain of NS3. The domain required for this cleavage
was mapped between amino acids 827 and 1207 of the
polyprotein at the C-terminus of NS2 [26]. NS2-3 was
called a metalloprotease based on observations that exo-
genous zinc stimulated protease activity and chelating
agents, like EDTA, were able to inhibit protease activity.
The zinc, which is known to be essential, may act struc-
turally to stabilise the NS3 structure at the active site.
Analysis of the region showed that amino acid require-
ments for effective NS2-3 cleavage vary between HCV
strains but deletion was required in both NS2 and NS3
to inhibit cleavage [27]. The crystal structure of the C-
terminal domain of NS2 has recently been determined
and reveals a dimeric protease containing two composite
active sites [28].
NS3
The NS3 is 67 kDa protein with multifunctional activity.
NS3 N-terminal has serine protease activity and a C-
terminal has NTPase/helicase activity [29]. NS3 protein
bound with ER membrane along with NS4A protein
[30]. HCV NS3 protease last 185 amino acids at the N-
terminus involved in cleavage between NS3-4A, 4A-4B,
4B-5A and 5A-5B [31]. The proposed catalytic activity
of HCV NS3 is due to three amino acid residues His-
1083, Asp-1107 and Ser-1165. Replacement of His-1083
and Ser-1165 with alanine abolished NS3 cleavage of the
HCV polyprotein without affecting protein structure of
NS3 [32,33]. The NS3 protein also contained a short
consensus sequence, which interacted with the catalytic
subunit of protein kinase A (PKA). This interaction led
to retention of the catalytic subunit of PKA in the cyto-
plasm preventing it entering the nucleus. PKA modifies
intracellular proteins by adding phosphate groups alter-
ing target protein function. Therefore, NS3/PKA inter-
actions may deregulate intracellular signalling [34]. NS3
serine protease recently turned out to influence the
innate cellular host defense by inhibition of RIG-I and
TLR3 signalling [35]. The NTPase/helicase domain of
NS3 resides in the C-terminal 465 residues of the NS3
protein.
The enzymatic activity of the NS3 NTPase/helicase
activity is indispensable for RNA replication. Putative
functions during replication could be to unwind replica-
tive double stranded RNA intermediates, to eliminate
RNA secondary structures or to separate the genome
from nucleic acid binding proteins. Recent advances in
the understanding of the molecular mechanisms of this
enzyme could enable a specific inhibition as a novel
antiviral strategy [36,37].
NS4A
NS4A is a 54 amino acids protein, which acts as a cofac-
tor for NS3 protein. The NS4A protein has an N-termi-
nus which is highly hydrophobic and deletion analysis
showed it to be involved in targeting NS3 to the ER
membrane [30]. It was proposed that last 20 amino
acids form a transmembrane helix, which anchors the
NS3/NS4A complex on the ER membrane. The interac-
tion between NS4A and NS3 is mediated between resi-
dues within the core of NS3 and the C- terminus of
NS4A. This interaction allows activation of the NS3
active site and more efficient protease cleavage [38].
NS4A is also required for the phosphorylation of NS5A
and can directly interact with NS5A. Deletion analysis
indicated that a region of amino acids in the centre of
NS5A (amino acids 2135 to 2139) was essential for
NS4A-dependent phosphorylation of NS5A [39].
NS4B
NS4B is a small hydrophobic 27 kDa protein, which play
an important role for recruitment of other viral proteins.
Topology studies have found NS4B contains 4 trans-
membrane domains. The cytoplasmic C-terminus of
NS4B and the N-terminus has a dual topology where
most faces the ER lumen [40]. NS4B interacts with
NS4A and therefore indirectly with NS3 and NS5A [41].
The NS4B protein was found to be an integral mem-
brane protein which was targeted to the ER and co-loca-
lized with other non-structural proteins in the ER
membrane [42]. Electron microscopy studies indicated
that NS4B induced morphological changes to the ER
forming a structure termed the membranous web. All
viral proteins were localized to this area suggesting a
site for replication complex formation [43]. Additional
immunofluorescence studies indicated that NS4B has
reduced mobility in these foci which may be due to oli-
gomerisation [44]. NS4B protein failed to show cyto-
pathic or oncogenic effects in the livers of transgenic
mice [45].
NS5A
NS5A is a hydrophilic phosphoprotein which plays an
important role in viral replication, modulation of cell sig-
naling pathways and interferon response [46,47]. NS5A
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association of NS5A is mediated by a unique amphipathic
alpha helix which is localized at the N-terminus [48,49].
NS5A play an important role in replication. Initial studies
indicated the association of NS5A with other viral pro-
teins which suggested its presence in replication com-
plexes [50]. Mutation of the amphipatic helix disrupted
membrane association and prevented formation of repli-
con-harbouring cells [51]. Mutations in NS5A were
essential for viral replication and establishing a replicon
cell line [52]. NS5A associated with lipid droplets when
expressed alone or as part of the polyprotein [53]. Struc-
tural analysis of the N-terminus showed NS5A contained
an essential zinc-coordination motif, which play an
important in structural integrity [54].
NS5A has initially attracted considerable interest
because of its potential role in modulating the IFN
response [55]. NS5A contain a region, which confers
resistance of the virus to interferon treatment [56]. This
region, called the interferon-a sensitivity-determining
region (ISDR), was later found to interact directly with
an IFN-a stimulated gene product, PKR protein kinase.
PKR protein kinase is activated by binding to double-
stranded RNA resulting eventually in cessation of pro-
tein synthesis. It was proposed that sequences in the
ISDR could be used to predict sensitivity or resistance
of HCV to IFN-a treatment [57].
NS5A has been proposed as having numerous interac-
tions with proteins affecting cell signalling. NS5A can
modulate the three main MAPK pathways involved in
host cell mitogenic signalling, which regulate growth
and activation. NS5A is able to regulate cellular signal-
ling by both pro- and anti- apoptotic mechanisms. It
has also been implicated in interfering with ROS path-
ways and phosphatidylinositol 3-kinase signalling path-
ways, which may lead to hepatocyte transformation and
HCC formation [46].
NS5B
The NS5B is a tail anchored protein of 65 kDa in size.
NS5B acts as RNA dependent RNA polymerase and
plays an important role in synthesis of new RNA gen-
ome [58]. Sequence analysis had identified an amino
acid motif GDD play an essential role for polymerase
activity [59]. The structural organization of NS5B is a
typical ‘right hand’ polymerase shape with finger, palm,
and thumb sub domains surrounding a completely
encircled active site [60]. Replication proceeds via synth-
esis of a complementary minus-strand RNA using the
genome as a template and the subsequent synthesis of
genomic plus-strand RNA from this minus-strand RNA
intermediate. As central component of the HCV repli-
case, NS5B has emerged as a major target for antiviral
intervention [61].
HCV virology
On the basis of nucleotide variation HCV is divided into
six major genotypes and more than 80 subtypes. The
highest sequence variability concentrated in hypervari-
able region of E1 and E2 glycoprotein. The lowest
sequence variability between genotypes is found in the
5’ untraslated region (UTR) which contain specific
sequences and RNA secondary structures that are
required for replication and translation functions. The
sequence variability is due to high replication rate and
lack of proofreading activity of RNA-dependent RNA
polymerase. The rate of nucleotide misincorporation is
approximately 10
-3 base substitutions per genome site
per year [62]. HCV infection is a highly dynamic process
with a viral half-life of only a few hours and production
and clearance of an estimated 10
12 virions per day in a
given individual [63]. All currently recognized HCV gen-
otypes are hepatotropic and pathogenic [64]. However, it
has been suggested that different genotypes do vary in
their infectivity and pathogenicity, thereby influencing
the rate of progression to cirrhosis and the risk of HCC
[65]. The duration of treatment should be based on the
HCV genotype and the pretreatment viral load. More-
over, several distinct but closely related HCV sequences
coexist within each infected individual.
There is 30-50% variation among viral genotypes and
15-30% among different subtypes while there is 1-5%
variation in nucleotide sequence from a single HCV
infected patient [66,67]. Genotype 1a and 1b is common
in Western Europe. Genotype 3 is most frequent in the
India, Nepal and Pakistan. Genotype 4 is the most com-
mon genotype in Africa and the Middle East. Genotype
5 is found in South Africa. Genotype 6 is found in
Hong Kong and Southeast Asia [68]. Genotype 3a has a
high prevalence worldwide, infecting up to 50% of
patients in several European countries as well as a high
percentage of HCV-infected individuals in many highly
populated countries in Asia (eg. India). In Pakistan the
major HCV genotype is 3a followed by 3b and 1a [69].
T h ep r e v a l e n c er a t ew a se s t i m a t e dt ob e5 . 3 %i nA f r i c a
(31.9 million cases), 4.6% in the Eastern Mediterranean
region (21.3 million cases), 3.9% in the West Pacific
region (62.2 million cases), 2.15% in Southeast Asia
(32.3 million cases), 1.7% in the Americas (13.1 million
cases) and 1.03% in Europe (8.9 million cases) [70].
Cell entry
Hepatitis C virus (HCV) entry is the first step of interac-
tions between virus and the target cell that is required
for initiation of infection. Recent studies suggest that
HCV entry is a slow and complex multistep process.
Several host cell surface molecules including glycosami-
noglycans, CD81, scavenger receptor class B type I (SR-
BI), members of the claudin family (CLDN1, 6 and 9)
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have been identified as putative HCV receptors or co-
receptors (Figure 2) [71,72]. GAGs and the LDL-R may
facilitate initial attachment to the host cell. This interac-
tion is probably mediated by the lipoproteins associated
with HCV virions. However, one cannot exclude direct
contact between HCV envelope proteins and these cel-
lular proteins. After the initial binding step, the particle
likely interacts with SR-BI and CD81. HCV E2 binds
with high affinity to the large external loop of CD81 and
CLDN1 acts at a late stage of the entry process [71].
These receptors have been shown to play an important
role for viral entry. Several human cell lines in spite off
expressing all known entry factors still remain non-per-
missive the entrance of HCV. This finding suggests the
requirement of some additional cellular factors that
mediate entry of the virus. In recent years, several host
restriction factors that protect cells from viral infection
have been identified such as EW1-2wint [73,74]. EW1-
2wint is a CD81 associated protein which is able to inhi-
bit HCV entry into target cells by blocking the interac-
tions between HCV glycoproteins and CD81. EWI-2wint
may interfere with actin polymerization during viral
entry or block signaling pathways necessary for viral
entry [75].
Viral RNA Transcription, replication and
Translation
The virus linked to its receptor complex, internalize and
then nucleocapsid is released into the cytoplasm. The
virus is decapsidated, and the genomic HCV RNA is
used both for polyprotein translation and replication in
the cytoplasm. Being a positive sense RNA, viral RNA
act as mRNA and is therefore directly translated. Trans-
lation of HCV RNA is not cap dependent like other cel-
lular RNAs in which cap bind to ribosomal machinery
for translation. Translation of HCV RNA is initiated by
binding the 5
/-IRES to ribosome. Translation of HCV
RNA occurs at rough endoplasmic reticulum and pro-
duces single polyprotein which cleave by co and post-
translationally by cellular and viral proteases, to produce
structural and non structural proteins. Hepatitis C virus
like other single stranded viruses of positive polarity
induces alteration in membrane. These changes in the
membrane termed as membraneous web [76,77]. NS5B
RNA-dependent RNA polymerase replicates the genome
by the synthesis of negative strand RNA. This negative
strand RNA serves as a template for the synthesis of
positive strand RNA. Replication and post-translational
processing appear to take place in a membranous web
made of the non-structural proteins and host cell pro-
teins called “replication complex”, located in close con-
tact with perinuclear membranes. Genome
encapsidation appears to take place in the endoplasmic
reticulum and nucleocapsids are enveloped and matured
into the Golgi apparatus before newly produced virions
are released in the pericellular space by exocytosis [49].
Treatment of HCV
HCV infection is rarely diagnosed during the acute
phase. Therefore, the treatment of acute hepatitis is very
limited. However, recent studies indicate that early
Figure 2 HCV receptors for cell entry.
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patients with chronic HCV infection (defined as infec-
tion persisting over more than six months with positive
HCV-antibody and HCV-RNA detectable in the serum)
are candidates for therapy. In past, the treatment of
standard is interferon alone or combination of inter-
feron with ribavirin. Interferon a is a cytokine which
plays an important role in innate immune responses
towards viruses. The molecular mechanism by which
IFN operates is mediated by its binding to receptors on
the surface of the target cells, which lead to a phosphor-
ylation cascade involving different tyrosine-kinases.
Finally, transcription factors are recruited to the nucleus
where they induce the synthesis of a number of antiviral
effectors proteins [80]. Interferon alpha alone result in
16-20% sustained response after 12 months of treatment
[81]. Ribavirin is a guanosine analog with a broad anti-
viral spectrum that enhances the sustained virological
response obtained with IFN treatment. Ribavirin show
antiviral effect by immune modulation of interferon sig-
naling pathway, inhibition of inosine monophosphate
dehydrogenase which results in GTP depletion. Ribavirin
also has direct antiviral effect on RNA dependent RNA
Polymerase and mutagenesis which results in reduction
in virion infectivity [82]. Interferon in combination with
ribavirin results sustained viral response in 35-40% of
patients [83]. Special precautions should be taken before
giving interferon to patients with decompensated cirrho-
sis, severe neutropenia, uncontrolled thyroid functions,
thrombocytopenia, drug or alcohol abuse and past or
current psychiatric illness.
Since the beginning of 2001, recombinant interferon
has been replaced by newly developed pegylated IFN
a2a and IFN a2b. The current standard therapy for
hepatitis C treatment consists of combination of pegy-
lated interferon a (Peg-IFN-a) with Ribavirin (RBV).
This combination regimen is successful in patients with
HCV genotypes 2 and 3 infection achieving HCV eradi-
cation rates of 75-90%. However, this combination is
much less effective in patients with genotypes 1 and 4
infections with eradication rates ranging between 45%
and 52% [84]. PegIFN a has an extended half-life com-
pared to Interferon a and therefore can be administered
only once a week. There are currently two pegIFN iso-
forms used for the treatment of chronic Hepatitis C
virus, pegIFN2a (Pegassays, administered in a dose of
180 μg/week) and pegIFN2b (PegIntron, given in a dose
of 1.5 μg/kg body weight). Pegasys is a 40 kDa molecule
with a half-life of 60-80 h and PegIntron is a 15 kDa
molecule with a half-life of 40 hours. Despite these dif-
ferences in half-life, both drugs are injected once a
week. The combination treatment can be administered
to the relapse cases and people who do not respond to
monotherapy. However, it remains difficult to treat
patients co-infected with HIV or HBV, patients with
high viremia titre, genotype 1 and 4, non-responders to
monotherapy and patients with solid organ transplanta-
tion. The HCV genotype 3, younger age and female gen-
der are significantly associated with high rate of
spontaneous clearance of infection [85]. The best possi-
ble indicator of effective treatment is a sustained virolo-
gical response (SVR), currently defined as undetectable
HCV-RNA in peripheral blood determined with the
most sensitive PCR technique 24 weeks after the end of
treatment (ETR) [84].
As HCV infection causes increased oxidative stress,
this can reduce the antiviral actions of interferon by
blocking the c-Jun N-terminal Kinase/Signal Transdu-
cers and Activator of Transcription (JNK/STAT) path-
way required for signalling by interferon. Therefore,
despite the best available treatment for HCV, some
patients do not respond to the therapy and relapse rate
are very high even after the completion of full course of
the treatment [86]. Cause for these differential responses
to treatment is currently unknown. Other factors asso-
ciated with non-response to treatment are high baseline
viral load as well as high fibrosis stage, old age, male
gender, African American race, obesity, alcohol intake
and changes in the host immune response, e.g. high
interleukin-8 (IL-8) and IL-10 serum levels [87]. The
numbers of NS5A/ISDR mutations have also been
shown to be relevant to the outcome of anti-HCV ther-
apy [88]. Moreover, IFN-a is associated with serious
adverse effects including leucopenia, thrombocytopenia,
neutropenia, depression, fatigue, and “flu-like” symp-
toms. The addition of ribavirin, although enhancing the
sustained viral response, is also associated with a serious
side effect like hemolytic anemia. These side effects are
sometimes dose limiting and may lead to discontinua-
tion of treatment [89]. These side effects result in dis-
continuation of therapy in 20% of patients [90]. Because
of extreme sequence variability within the HCV genome,
development of an effective vaccine against HCV infec-
tion has proven to be very difficult. Furthermore, combi-
nation therapy is expensive. There is therefore a great
need to develop new therapeutic approaches that effec-
tively block the different HCV genotypes and avoid the
appearance of resistant quasispecies.
Immune responses in HCV infection
Innate and adaptive immune responses play an impor-
tant role in viral infection. In the liver the innate
immune responses are due to NK cells, NKT cells, kupf-
fer (liver macrophages) and a rapid interferon response
exerted by infected liver cells. NK and NKT cells per-
form cytotoxic lysis of infected cells by releasing gran-
ules containing perforin and proteases (granzymes). NK
and NKT cells also produce large amount of type II
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stranded RNA intermediates during HCV replication
result in the activation of type I interferon gene. The
host cells recognize double straded RNA via Toll like
receptor 3 (TLR-3) [91]. The activation of type I inter-
feron, interferon a and interferon b, play an important
role in early defense system of viral infection. One study
showed that the mice lacking interferon a and inter-
feron b failed to clear HCV infection [92]. Similarly,
humans with genetic defects in STAT-1, which is
involved in the signaling cascade of the IFN system, die
of viral disease at an early age (Dupuis et al., 2003).
Another study in chimpanzees showed that interferon
type 1 induced double-stranded RNA-dependent protein
kinase (PKR), 2’-5’ oligoadenylate synthetase (OAS) and
Mx genes upon acute HCV infection, which play an
important role to inhibit replication of HCV and induce
apoptosis in infected hepatocytes [93]. Natural killer
cells play an important role and can eliminate virus
without any detectable HCV specific T cells responses
in chimpanzee [94].
Adaptive immune response consist of humoral
immune response such as antibody producing B cells
and cellular immune respons e ss u c ha sC D + 4Th e l p e r
cells (TH) and CD8+ cytotoxic T lymphocytes (CTLs).
Virus-specific antibodies are usually detectable approxi-
mately 7-8 weeks after HCV infection [95]. It is still no
completely underdtood whether or not these antibodies
neutralize HCV infectivity. HCV infection neutralize in
vitro with the treatment of antibodies [96] but naturally
acquired antibodies fail to neutralize HCV infection in
chimpanzee and human. Now, important progress has
been made by the production of infectious lentiviral
pseudotype particles bearing native HCV envelope gly-
coproteins. These pseudoparticles have been used to
show cross-viral genotype neutralization of HCV by
serum antibodies from chronically infected subjects
[13,97]. CD+4 T helper cells (TH) and CD8+ cytotoxic
T lymphocytes (CTLs) play an important role in virus
particle clearance [98,99]. CD4+ T cells recognize anti-
gens presented by MHC class II molecules on the sur-
face of professional antigen presenting cells (APCs).
CD4+ T cells perform multiple effector functions,
including direct activation of macrophages and antigen-
specific B cells as well as activation of CD8+ T cells.
CD8+ T cells recognize antigens presented by MHC
class I molecules on the surface of infected cells. CD8+
T cells perform different effector functions, such as the
killing of infected target cells and the secretion of cyto-
kines such as IFN gamma and TNF a that can inhibit
viral replication without killing the infected cell [100].
However, detection of CD4+ and CD8+ T cell responses
during acute phase of infection is an important predic-
tion of outcome of infection.
Viral evasion strategy to HCV
HCV interferes with innate and adaptive immune
responses in several ways. HCV impair the interferon
signaling pathway and HCV NS3/4A block RIG-1 activa-
tion and translation of IRF-3. HCV core protein inter-
feres with the JAK/STAT pathway by activating the
JAK-STAT signaling inhibitor SOCS-3 [101], increases
the degradation of STAT1 and inhibits activation and
translocation of STAT1 [89,102]. HCV E2 inhibit pro-
tein kinase receptor (PKR) activity and natural killer cell
function [103,104]. HCV NS5A also plays an important
role in escape of antiviral action of interferon. NS5A
consists of 40 amino acid sequence termed as interferon
sensitive region (ISDR) which plays an important role in
responsiveness of interferon therapy. NS5A also inter-
feres with the 2-5 OAS/RNaseL pathway by binding to
2-5 OAS [105]. Moreover, NS5A was shown to directly
bind to protein kinase receptor ( PKR) and down-regu-
late the PKR expreswsion [106]. NS5A induces IL-8, a
chemokine which inhibits the antiviral actions of IFN
[107]. Envelope protein E2 crosslinks the HCV receptor
CD81, thereby inhibiting cytotoxicity and IFN produc-
tion by NK cells [103,104].
HCV escape from adaptive immune response through
several different mechanisms such as mutational escape
and functional anergy (failure) of virus specific T cells.
Cellular immune responses such as CD4+ T helper cells
(TH) and CD8+ cytotoxic T lymphocytes (CTLs) cause
long lasting inflammatory reactions resulting in liver cir-
rhosis and hepatocellular carcinoma [108]. Weak T cell
responses resulted poor controlled viremia and persis-
tence [98]. In those patients that have been chronically
infected, HCV specific CD8+ T cells may partially con-
trol viral replication as well as contributing to progres-
sive liver disease. Mutational escape of HCV virus from
t h ea d a p t i v ei m m u n er e s p o n s eh a so n eo ft h em a j o r
viral evasion strategies. Mutational changes in virus par-
ticle are due to lack of proofreading activity of RNA
dependent RNA polymerase and high replication rate
such as 10
12 virions per day. Sequence changes in the
hypervariable region of the E2 envelope glycoprotein
result in escape from B cell epitopes. Viral amino acid
substitutions that inhibit HCV-specific T cell recogni-
tion have initially been observed in chronically HCV
infected patients [109,110] and chimpanzees [111]. HCV
mutations affect virus specific CD8+ T cell responses by
decreasing binding affinity between epitope and MHC
molecule by decreasing T cell receptor (TCR) recogni-
tion [112] and impairing proteosomal processing of
HCV antigens[113].
Another important possible mechanism of immune
evasion is functional anergy of virus-specific T cells.
Several studies have shown that dysfunction of CD8+ T
cells occurs in acute as well as chronic HCV infection
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Page 7 of 10[98,114]. HCV-specific CD8+ T cells may be impaired in
their proliferative capacity, cytotoxicity, and ability to
secrete TNF a and IFN l [115].
Conclusion
HCV infection is a serious global health problem necessi-
tating effective treatment. Presently, there is no vaccine
available for prevention of HCV infection due to high
degree of strain variation. Current therapeutic options for
hepatitis C are limited, especially for genotype 1. For geno-
types 2 and 3, pegylated interferon in combination with
ribavirin, can lead to a sustained virological response in up
to 80% of patients [116]. However, the therapy is expensive
and often associated with side effects that may lead to dis-
continuation of therapy. In this review, we summarize
molecular virology, replication and immune responses
against HCV and discussed how HCV escape from adap-
tive and humoral immune reseponses. Recent advances in
our understanding of HCV structure, genome lifecycle and
immune responses have revealed numerous target sites for
potential pharmacological intervention. These should help
in further improving HCV treatment and development of
vaccine against HCV.
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